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Abstract 
Introduction: Premenstrual syndrome (PMS) is a condition characterized by a num-
ber of behavioral, psychological and physical symptoms recurring cyclically during 
the luteal phase of the menstrual cycle. The uncertainty in the pathogenesis of PMS 
has led to many treatment protocols being suggested as possible therapies. The pres-
ent study was carried out to compare the effects of echinophora-platyloba and fennel 
extracts on the PMS against placebo in students of Shahrekord University of Medical 
Sciences in 2008. 
Methods: In this single-blind randomized clinical trial, 90 students with moderate to 
severe PMS enrolled in the study and were randomely divided into three equal 
groups. The first group received echinophora-platyloba extract, the second group 
received fennel extracts and the third group received placebo. The severity of PMS 
was measured by Daily Record of Severity of Problems (DRSP) questionnaire at the 
end of the first and second menstrual cycles before the intervention and the results 
were compared with them after the intervention. Data was analyzed using Dunn, 
Kruskal Wallis, and Pearson correlation tests by SPSS (v. 11.5) and p<0.05 was 
considered statistically significant.  
Results: There were not any significant differences in the means of premenstrual 
syndrome scores before the intervention among the three groups (100.8±22.1 in 
echinophora-platyloba group, 101.3±27.1 in fennel group and 104.3±19.5 in placebo 
group, p>0.05), but the differences were significant after the intervention (49.7±23.2 
in echinophora-platyloba group, 64.4±27.5 in fennel group and 79.1±28.1 in placebo 
group, respectively, p<0.001). No significant differences were seen between the 
echinophora-platyloba and fennel groups. 
Conclusion: The echinophora-platyloba and fennel extracts could reduce the sever-
ity of PMS. The effects of echinophora-platyloba and fennel were similar and greater 
than the placebo. Administration of the extracts of these herbs is suggested for re-
lieving the signs and symptoms of PMS.  
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Introduction 
       remenstrual syndrome (PMS) is characterized  
       by a number of behavioral, psychological and 
physical symptoms recurring cyclically during the 
luteal phase of the menstrual cycle and they disap-
pearing in the first days of menstruation (1).  
 
 
 
 
More than fifty symptoms have been found 
which are contributed to PMS. The most common 
symptoms of PMS are irritability, mood swings, 
anxiety, depression, breast tenderness, bloating 
and headache (2, 3). Due to the variety and sever-
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ity of the symptoms, it is difficult to estimate the 
exact prevalence of PMS, but previous studies 
have reported a 20-90% estimate (4). With the 
limited diagnostic criteria, the prevalence of PMS 
reaches to 2-6% in reproductive age (1). Some-
times premenstrual syndrome and related behav-
ioral symptoms are legally important and are con-
sidered as a defense against criminal acts and 
sometimes they can lead to murder (5 - 7). A 
study reported that PMS caused a 27.5% reduc-
tion in women’s work efficacy and 22% had prob-
lems in working relationship. This study also 
demonstrated that PMS led to problems with 
husband (83%), problems with children (61%) 
and social relationships disorders (41.5%) (8). 
The etiology of PMS is largely unclear and 
different theories have been suggested, including 
hormone imbalances, hypoglycemia, hyperpro-
lactinaemia, psychological causes, reduced endor-
phins release, ovary infections, deficiency of es-
sential fatty acids, dysfunction in acid and base 
balance, imbalances in prostaglandins, vitamin 
and mineral deficiencies (9 - 12).  
Pathophysiology of PMS is unknown and dif-
ferent therapeutic protocols have been suggested 
for its treatment. Non-pharmacological treatments 
include changes in dietary habits, reduction in salt 
intake, reduction in animal fat consumption, exer-
cise, stress reduction and availability of support 
systems. Pharmacological treatments include 
GnRH analogues, spironolactone, danazol, alpra-
zolam, mephenamic acid, gamalinoleaic acid, and 
fluoxetine (13 - 15).  
In recent years, use of herbs has been considered 
in the treatment of premenstrual syndrome (16 -  
19). Echinophora-platyloba (E. platyloba) and 
Foeniculum vulgare (Fennel) are herbs that are 
traditionally used for menstrual disorders. Echino-
phora platyloba belongs to Umbelliferae family 
and consists of four species including E. cinerea, 
E. platyloba, E. orientalis and E. sibthorpiana. The 
two aforesaid herb species are exclusive of Iran 
(20). E. platyloba species is known by different 
local names of Khoshariz, Tigh Touragh, Tigh 
Masti, Khoshandar, Kouzang, Tanghez or Khou-
sharouz. This plant is a pasture plant used for fla-
voring foods, cheese and yoghurt (20, 21). Sadraei 
et al (20) reported that E. platyloba extract re-
duced the ileum contractions in rats. Anti-fungal 
effects of E. platyloba has been depicted on a 
number of common dermatophytes (21). The anti-
candida effects of this plant was compared with 
amphotericin by Mahbobi et al. (22) and it was 
shown that this plant was effective in the treat-
ment of candida albicans.  
Fennel (Foniculmn vulgare) has been shown to 
have anti-inflammatory, anti-spasmodic, anal-
gesic, diuretic, laxative, carminative and expector-
ant effects. In addition, because of its antioxida-
tive effects, it is also useful for digestive and 
nervous disorders (23 - 25). 
Torke Zahrani, et al (26) reported that fennel 
extract reduced the severity of dysmenorrhea. The 
effects of fennel and Mephenamic acid was stud-
ied on dysmenorrhea and it was demonstrated that 
both drugs reduced dysmenorrhea compared to 
placebo (27). Fennel essence can reduce the fre-
quency and intensity of contractions in rat uterus 
(28). To the best of our knowledge, the effects of 
echinophora-platyloba and fennel extracts on pre-
menstrual syndrome (PMS) has not been reported 
yet. The purpose of the present study was to 
compare the effects of echinophora-platyloba and 
fennel against placebo on premenstrual syndrome 
in the students of Shahrekord University of 
Medical Sciences in Iran. 
 
Methods 
This single-blind randomized clinical trial study 
was done on 250 female university students aged 
18-25 years in Shahrekord University of Medical 
Sciences in Iran. The Ethics Committee approved 
the study (No. 352.87-1-3 on 12.5.2008) and the 
study was registered at the Iranian Registry of 
Clinical Trials and the identifier being IRCT 
138810263078N1. 
The participants were requested to fill the Daily 
Record of Severity of Problem (DRSP) two cycles 
before the intervention and then the severity of 
premenstrual syndrome was evaluated for all sub-
jects. The daily record of severity of problem 
form is a standard tool for detecting the intensity 
of PMS and its validity and reliability have been 
approved by Borenstein and et al (29). This form 
determines the severity of PMS using five items, 
including: anxiety symptoms (tension, emotional 
changes, irritation, reduction in concentration and 
fear), depressive symptoms (depression, hopeless-
ness, amnesia, crying, dizziness, mood disorders, 
sleep disorders, isolation and loss of interest to 
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daily activities), emotional symptoms (headache, 
sweating, hot-flushes, increased appetite, heart 
palpitation, fatigue, reduced energy, and inability 
to do the daily activities), fluid and electrolyte 
retention symptoms (increases in weight, edema, 
breast tenderness, backache, abdominal cramps 
and pain in muscles and joints) and  somatic 
symptoms (acne, urinary frequency, constipation  
and inflammation of nose)] (29). Based on the 
DRSP form, scores ranging from 0 to 4 were 
allocated to evaluate the severity of symptoms as 
it follows: 
0: absence of symptoms, 1: mild (the individual 
seldom has problems in daily activities), 2: mod-
erate (the individual has problems in maintaining 
daily activities, but can go to work or school), 3: 
severe symptoms (the individual is not able to do 
daily activities) and 4: very intense (the individual 
is confined to bed). Considering the purpose of 
the present study, the students with moderate and 
severe PMS were selected for the intervention.  
All the students were also asked about their 
menstrual patterns; such as duration of menstru-
ation, menstrual interval, dysmenorrhea, familial 
history of PMS and use of drugs for the reduction 
of PMS. Students with pelvic inflammatory dis-
ease (PID), any chronic diseases, drug use or with 
any stressor factors were excluded from the study. 
Finally, ninety students with the highest PMS 
scores, were selected and they were randomly 
assigned into three equal groups. The first group 
received echinophora-platyloba extract, the sec-
ond group received fennel extract and the placebo 
group received strile water. The amount of the 
given extracts and the placebo was 30 drops, 
every 8 hours, 3 days before until 3 days after the 
onset of menstrual bleeding. The subjects com-
pleted the DRSP form at the end of their first and 
second menstrual cycles. After the interventions, 
the severity of PMS was evaluated again. The 
students were blind about the kind of drug 
throughout the study. Data was analyzed by Dunn, 
Kruskal-Wallis and Pearson correlation tests, 
using SPSS and a p<0.05 was considered signifi-
cant. 
 
Results 
From the total number students who participated 
in the study, 4 persons in the echinophora-
platyloba group, 2 persons in the fennel group and 
3 persons in the placebo group did not complete 
the study. The demographic data of the students 
have been presented in Table 1. As shown in the 
table, no significant differences were observed for 
age, body mass index, age at menarche, age at 
dysmenorrhea onset and duration of menstruation 
between the three groups. In addition, menstrual 
cycle intervals and family histories of PMS were 
similar among the groups.  
As shown in Table 2, there were no significant 
differences regarding the total PMS scores among 
three groups before the intervention (P=0.58), but 
differences were significant after the intervention 
(P=0.009). Statistical analysis demonstrated that 
the total premenstrual syndrome scores has been 
reduced upon the treatments in three groups 
(P<0.001). It means that echinophora-platyloba, 
fennel and placebo reduced the severity of PMS, 
but the effects of echinophora-platyloba was more 
significant (Table 2). When the effects of echino-
phora-platyloba was compared with fennel ex-
tract, there was no significant differences between 
the two extracts (P=0.08). There were no signifi-
cant correlations between the age and body mass 
index of the individuals with symptoms of PMS 
before and after the intervention (P>0.05).   
Table 1. The demographic characteristics of the participants 
 
Group Echinophora-platyloba Fennel Placebo 
P-Value 
Characteristics M±SD M±SD M±SD 
Age (year) 20.3±1.6 19.9±1.01 20.4±1.9 0.471 
Body mass index (kg/m2) 20.7±2.7 19.8±4.59 19.7±4.1 0.631 
Age at menarche (year) 13.50±1.52 14.10±1.19 14.12±1.18 0.147 
Age at dysmenorrhea onset (year) 14.42±1.87 15.32±1.38 15.33±1.46 0.063 
Duration of menstruation (day) 6.26±1.25 6.21±1.19 6.98±1.34 0.058 
 
 The scores related to symptoms of PMS and the total mean of PMS have been presented in Table 2  
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Discussion 
The findings of this study showed that echino-
phora-platyloba and fennel extracts, as well as 
placebo, reduced the intensity of premenstrual 
syndrome in students and the effects of the two 
extracts were more significant than these of pla-
cebo.  
Echinophora-platyloba is one of the four species 
in Iran (20) which is also used for food. Anti-
microbial and anti-fungal effects of echinophora 
sibthorpiana have been reported before (22, 23). 
In addition, Sadraei et al. showed that echino-
phora sibthorpiana extract reduces the rat ileum 
contractions in vitro (20). A previous study which 
was carried out on the echinophora platyloba, 
revealed that this herb contains elements such as 
saponins, alkaloids and flavonoids. Saponines are 
elements with toxic effects (30). As far as we 
know, the effects of echinophora platyloba and 
fennel extracts on premenstrual syndrome have 
not been studied yet. Previous findings from 
different medicinal plants have shown that use of 
herbs is effective in the luteal phase of the men-
strual cycle and does not need to be used through-
out the cycle (31). In the present study, the effects 
of echinophora platyloba and fennel extrats were 
investigated in the luteal phase too. 
Our findings indicated that during the two cycles 
before the intervention, the severity of PMS was 
similar in the three study groups, but after the 
intervention the differences were significant. It 
means that, echinophora platyloba had the highest 
Table 2. Comparison of PMS scores in echinophora-platyloba, fennel and placebo groups 
 
Treatment group E-chinophora-platyloba Fennel Placebo P-Value 
PMS Symptoms (before and  
after the intervention M±SD M±SD M±SD 
Anxiety   
Before                                  24.3±5.1 22.8±6.2 23.9±6.0 0.72 
After 12.00±4.3 14.1±6.1 23.4±5.5 0<0.001 
Reduction                               12.3±4.7 8.7±4.6 0.4±3.1 0<0.001 
Depression 
Before                                    28.9±6.8 28.8±9.4 28.8±6.7 0.95 
After 14.0±6.1 17.8±9.0 21.2±6.7 0.04 
Reduction                               15.9±5.9∗ 11.0±5.5 8.9±8.6∗ 0.029 
Emotional 
Before                                   18.4±6.3 20.0±6.4 21.8±6.0 0.06 
After 10.3±6.3 12.7±5.3 14.2±8.0 0.23 
Reduction                               9.3±5.9∗ 7.6±4∗ 5.4±7.5∗ 0.29 
Fluid Retention 
Before                                    19.0±7.0 20.5±7.0 20.1±7.2 0.71 
After 9.5 ±6.5 13.6±5.5 13.0±6.1 0.06 
Reduction                               10.5±6.4∗ 6.9±5.7 8.2±6.7∗ 0.15 
Somatic 
Before                                 10.1±4.4 9.3±4.5 9.7±3.8 0.73 
After 4.2±4.5 5.9±3.6 6.4±5.6 0.20 
Reduction                               6.0±4.2 3.5±3.1 2.8±4.9∗ 0.10 
Total score of PMS 
Before                                    100.8±22.1 101.0±27.2 104.3±19.5 0.58 
After                                      49.7±23.1 64.4±27.5 79.1±28 0.009 
Reduction                               55.3±18.5∗ 38.7±16.1∗ 25.5±22.4 0<0.001 
 
∗ The reason of difference in the reduction mean of premenstrual symptoms with the mean of symptoms 
before and after the intervention, is that, a number of participants didn’t answer to some of questions after the 
intervention 
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and placebo had the lowest effects in the reduc-
tion of PMS symptoms. Considering the effects of 
age, BMI, age at menarch, and age at dysmenor-
rhea on premenstrual syndrome, since the partici-
pants were randomely allocated to each group and 
there was not a significant difference in these 
variables between the groups, and also the 
Pearson correlation test did not show a significant 
correlation between premenstrual syndrome and 
these variables. 
Among the five classifications of PMS symp-
toms, which include anxiety, depression, emotion-
al, fluid and electrolyte retention and somatic 
symptoms, the highest effect was seen on anxiety 
and depressive symptoms. Aghajani and co-work-
ers reported that the Vit-agnus castus can reduce 
somatic and psychological symptoms (32). Other 
studies reported that medicinal plants could re-
duce the severity of PMS up to 45%- 70% (8, 32). 
In comparing the effects of echinophora platyloba 
and fennel extracts, we found that both plants had 
similar effects in reducing the intensity of PMS. 
Psychological effects of placebo have been report-
ed by previous studies (33) and the effect attri-
buted to placebo in our study may also be due to 
these effects. 
 
Conclusion 
Echinophora platyloba and fennel extracts, as 
well as placebo, reduced the severity of premen-
stural syndrome. The effects of Echinophora 
platyloba and fennel were similar and both ex-
tracts were effective on symptoms of anxiety and 
depression. More studies with bigger sample sizes 
are needed for the use of echinophora platyloba 
and fennel essences, instead of their extracts, to be 
suggested for PMS treatment. 
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